Before using any supplement, always consult a doctor, pharmacist, or nephrologist to ensure its safe for you
British Association of Aesthetic Plastic Surgeons
A systematic review of the association between erectile dysfunction and cardiovascular disease (Vlachopoulos et al., 2013)
No changes in IGF-1 levels
Another Ozempic drawback anyone comparing Byetta vs Ozempic should consider is the long-lasting effects
Revenue , By Geographical Segments, 2022 (%) Figure 142: Sanofi Revenues, 2020-2022 (USD Million) Figure 143: Sanofi Revenues, By Geographic Segments, 2022 (%) Figure 144: Sanofi Revenue , By Business Segments, 2022 (%) Figure 145: AstraZeneca PLC Revenues, 2020-2022 (USD Million) Figure 146: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%) Figure 147: AstraZeneca PLC Revenue , By Business Segments, 2022 (%) Figure 148: Novo Nordisk Revenues, 2020-2022 (USD Million) Figure 149: Novo Nordisk Revenues, By Geographic Segments, 2022 (%) Figure 150: Novo Nordisk Revenue , By Therapeutic Area, 2022 (%) List of Tables Table A2: Details of GLP-1 Agonist in several stages of clinical trials Table A3: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A4: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A5: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A6: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A7: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A8: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A9: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A10: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A11: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A12: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A13: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A14: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A15: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A16: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A17: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A18: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A19: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A20: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A21: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A22: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A23: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A24: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A25: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A26: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A27: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A28: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A29: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A30: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A31: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A32: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A33: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A34: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A35: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A36: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A37: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A38: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A39: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A40: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A41: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A42: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A43: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A44: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A45: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A46: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A47: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A48: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A49: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A50: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A51: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A52: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A53: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A54: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A55: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A56: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A57: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A58: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A59: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A60: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A61: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A62: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A63: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A64: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A65: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A66: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A67: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A68: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A69: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A70: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A71: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A72: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A73: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A74: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A75: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million) Table A76: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million) Table A77: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million) Table A78: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million) Table A79: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million) Table A80: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million) Table A81: Eli Lilly and Company Key Financials, 2020-2022 Table A82: Pfizer Key Financials, 2020-2022 Table A83: Sanofi Key Financials, 2020-2022 Table A84: AstraZeneca PLC Key Financials, 2020-2022 Table A85: Novo Nordisk Key Financials, 2020-2022 Companies Mentioned Eli Lilly and Company Pfizer Sanofi AstraZeneca PLC Boehringer Ingelheim Novo Nordisk
